Elvitegravir



Better Known as: N/A

 * Marketed By: Gilead Sciences
 * Major Indication: Human Immunodeficiency Virus Infection
 * Drug Class: Retroviral Integrase Inhibitor
 * Expected FDA Approval: 2011
 * Projected 2013 Sales: $460 Million
 * Importance: It is expected to be the next effective HIV treatment to come to market. Expected to be the second Retroviral Integrase inhibitor approved. Currently in phase III clinical trials. Results from phase II trials indicate that the once-daily treatment was more effective than current HIV Protease inhibitor combinations.
 * See Pharmaceutical Drugs for more information about other drugs and disorders.

Mechanism of Action
Retroviral Integrase is produced by the HIV retrovirus, enabling HIV to integrate its genetic material into the DNA of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit. HIV retroviral integrase forms "intasomes" when it complexes with viral DNA. The integrase domains interact extensively with the viral DNA, binding the nucleotide chains precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. Elvitegravir binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. Elvitegravir binds to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.